Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)

Phase Distribution

Ph not_applicable
2
67%
Ph early_phase_1
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Early Phase 1

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 11 (33.3%)
N/A2 (66.7%)

Trials by Status

terminated133%
completed267%

Recent Activity

0 active trials
Showing 3 of 3
completednot_applicable

Methotrexate in Retinal Detachment With Proliferative Vitreoretinopathy

NCT07058337
completedearly_phase_1

Methotrexate Infusion and Intrasilicone Injection During Diabetic Vitrectomy

NCT06038968
terminatednot_applicable

Autologous Blood for Full-thickness Macular Hole

NCT05494229

Clinical Trials (3)

Showing 3 of 3 trials
NCT07058337Not Applicable

Methotrexate in Retinal Detachment With Proliferative Vitreoretinopathy

Completed
NCT06038968Early Phase 1

Methotrexate Infusion and Intrasilicone Injection During Diabetic Vitrectomy

Completed
NCT05494229Not Applicable

Autologous Blood for Full-thickness Macular Hole

Terminated

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3